A self-immunomodulating myoblast cell line for erythropoietin delivery
- 1 January 2001
- journal article
- Published by Springer Nature in Gene Therapy
- Vol. 8 (1) , 58-66
- https://doi.org/10.1038/sj.gt.3301356
Abstract
At the forefront of medicine, Gene Therapy brings you the latest research into genetic and cell-based technologies to treat disease. It also publishes Progress & Prospects reviews and News and Commentary articles, which highlight the cutting edge of the field.Keywords
This publication has 36 references indexed in Scilit:
- Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblastsGene Therapy, 1998
- CD40 AND CD154 IN CELL-MEDIATED IMMUNITYAnnual Review of Immunology, 1998
- Strong Immunogenic Potential of a B7 Retroviral Expression Vector: Generation of HLA-B7-Restricted CTL Response Against Selectable Marker GenesHuman Gene Therapy, 1998
- Central Nervous System Delivery of Recombinant Ciliary Neurotrophic Factor by Polymer Encapsulated Differentiated C2C12MyoblastsHuman Gene Therapy, 1996
- IMMUNOSUPPRESSION WITH MONOCLONAL ANTIBODIES AND CTLA4-Ig AFTER MYOBLAST TRANSPLANTATION IN MICETransplantation, 1996
- SECRETION OF CTLA4IG BY AN SV40 T ANTIGEN-TRANSFORMED ISLET CELL LINE INHIBITS GRAFT REJECTION AGAINST THE NEOANTIGEN1Transplantation, 1996
- Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathwaysNature, 1996
- CD28/B7 SYSTEM OF T CELL COSTIMULATIONAnnual Review of Immunology, 1996
- IMMUNOMODULATION OF PANCREATIC ISLET ALLOGRAFTS IN MICE WITH CTLA4Ig SECRETING MUSCLE CELLSTransplantation, 1995
- Activation of human dendritic cells through CD40 cross-linking.The Journal of Experimental Medicine, 1994